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INTRODUCTION
Rituximab is a chimeric anti-CD20 monoclonal antibody
that is used to treat some hematological malignancies
such as B-cell lymphomas, and various autoimmune
diseases including immune thrombocytopenic purpura,
systemic lupus erythematous, rheumatoid arthritis, and
autoimmune hemolytic anemia. The most common
side effects include fever, chills, and rigors. Respiratory
complications such as cough, bronchospasm, sinusitis,
and rhinitis have also been reported in 30% of patients
in clinical trials.1 Rituximab-induced lung injury is a very
rare but potentially fatal complication. We report a case
of fatal single agent rituximab-induced nonspecific
interstitial pneumonia to increase awareness about this
serious side effect and review the current literature.

However, she clinically continued to deteriorate during
this time and she eventually required intubation and
mechanical ventilation. Bronchoscopy was performed
which was negative for infection including any aerobic or
anaerobic bacteria, acid-fast bacilli, fungus, or virus. The
patient further decompensated with hypoxemic respiratory
failure and expired on the third week of admission despite
multiple rounds of resuscitation. The patient’s family
agreed to a limited autopsy of her lung which revealed a
histologic pattern of nonspecific interstitial pneumonia
with uniform thickening of the alveolar septa with a
monotonous lymphoid infiltrate. There was spatial and
temporal homogeneity seen (Figure 2).

CASE PRESENTATION
This case involves a 72-year-old female with stage IV
marginal-zone lymphoma (diffuse nodal and splenic
involvement) who required therapy due to transfusiondependent anemia and was initiated on single-agent
rituximab (four weekly doses at a dose of 375 mg/m2).
She tolerated the first two infusions well, but started to
feel short of breath after her third infusion. By the time
she arrived to the infusion center for her fourth dose,
she was short of breath at rest and was found to be
hypoxic to 68% on room air. Of note, the patient had
COPD with a 30 pack-year smoking history, quit three
years ago, but had no previous oxygen requirement.
She was admitted to the hospital where she was started
on broad-spectrum antibiotics and placed on five liters
of oxygen delivered via nasal cannula. A chest CT scan
with contrast showed extensive bilateral ground-glass
opacities with interlobular septal thickening (Figure 1a).
On the second day of admission, the patient became
hypoxic to 70% on six liters of supplemental oxygen, but
did not tolerate bilevel positive airway pressure so she
was transferred to the medical intensive care unit.
Methylprednisolone 125 mg every six hours was started
intravenously for possible rituximab-induced lung
reaction in the intensive care unit. A repeat CT scan of
the chest two weeks later revealed improvement in the
bilateral airspace opacities (Figure 1b).
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Figure 1. CT chest of this patient on admission (a) showed extensive ground glass
opacification and septal thickening throughout the lungs bilaterally. (b) After two
weeks of steroid therapy, the CT chest showed improvement in the extensive
bilateral airspace opacities.

depletion, causing cytotoxic T lymphocyte dysregulation,
thereby promoting lung damage.2,14,15
Similar to our patient, typical RTX-ILD is subacute in onset
becoming symptomatic after a median of 4.1 doses.2 The
earliest presenting symptoms are often dry cough,
exertional dyspnea, and fever. Common radiologic
findings on CT scan include ground glass opacification,
alveolitis, pulmonary fibrosis, alveolar hemorrhage,
pleural effusion, and consolidation. Our patient did not
get pulmonary function tests, but these would typically
show a restrictive pattern on spirometry and significant
DLCO reduction. Biopsy is not usually done but most
commonly show pulmonary inflammation, and a range
of histologic patterns can be seen including nonspecific
interstitial pneumonia as was seen in our patient.1
Figure 2. The biopsy of the autopsy lung showed histologic features of uniform
interstitial inflammation with varying degrees of fibrosis consistent with
nonspecific interstitial pneumonia.

DISCUSSION
Nonspecific interstitial pneumonia (NSIP) is a type of
idiopathic interstitial pneumonia that is characterized by
spatially and temporally uniform interstitial inflammation
with varying degrees of fibrosis on pathology.6 NSIP can
be idiopathic but can be associated with the toxic effects
of drugs and occupational exposure. Rituximab has been
reported in the literature to be a cause of NSIP, as well as
other non-infectious-related interstitial lung diseases.2-5,7
The complicating factor with diagnosis and prognosis of
rituximab-induced lung disease (RTX-ILD) is that rituximab
is often used with concomitant chemotherapy or
radiation which may also cause pulmonary toxicity, unlike
our patient who only had rituximab monotherapy.
Although several systematic reviews of the literature have
noted RTX-ILD with rituximab monotherapy, only two
reviews directly compared rituximab monotherapy to
concomitant therapy.2,4,5,8 Blitzen et al. noted in a review
of pediatric cases that the clinical presentations and
outcomes were similar in patients with and without
concomitant chemotherapy.7 Lioté et al. noted in their
systematic review that nine patients experienced no
further respiratory symptoms when chemotherapy was
restarted without rituximab, implying that rituximab was
the culprit for lung injury.5
The mechanism behind RTX-ILD is complex and remains
unclear, but is thought to be secondary to complementdependent cell lysis, antibody dependent cellular toxicity,
and tumor necrosis factor alpha release.1,3,4,9,10,11 Rituximab
efficiently eliminates B cells in lung tumors, normal lung
tissues, and lung-associated lymph nodes, which may
lead to normal lung injury through pro-inflammatory
effects of activated cytokines, inflammatory mediators,
and angiogenic factors.12,13 There may also be interference
of lymphocyte crosstalk due to prolonged B-cell

The recommended treatment is prompt discontinuation
of rituximab, initiation of steroids, and supportive therapy.
However, there are no recommendations on dose,
route, or duration of steroids.1-4,7,8 In a number of cases
such as ours, high doses of steroids were unable to
prevent death.2 Our patient received high-dose steroids
on the second day of admission, but despite improvement
on imaging after steroid initiation our patient ultimately
expired. Improvement on her imaging suggests the
steroids were treating the NSIP, but the treatment could
have been initiated too late or the injury to an already
diseased lung could have been too devastating.
If the patient survives an acute episode of RTX-ILD, it is
unclear whether to avoid or reintroduce rituximab, as
there have been cases of both positive and negative
results.5 As for other treatment options, inhibiting the
complement pathway or the activation of Nod-like
receptor pyrin domain-containing protein 3 (NLRP3)
inflammasome have also been discussed in the literature
but no cases have been reported thus far.9,13 Wu et al.
reported a case of RTX-ILD treated with methylprednisolone together with an antibody against tumor
necrosis alpha therapy (Etanercept), but the benefits
were only transient.3 Further investigation into treatment
options and guidelines for RTX-ILD is necessary.
The risk factors for development of RTX-ILD remain
unclear. Apart from Vulsteke et al. who reported a case of
acute exacerbation of idiopathic pulmonary fibrosis with
rituximab use, most studies have looked at RTX-ILD in
patients with no previous lung injury.16 Franzen et al. also
identified cigarette smoking as a possible risk factor for
pulmonar y function decline with rituximab and
recommended smoking cessation during treatment.17 Our
patient had an extensive smoking history and COPD and
the further damage that rituximab had on her lung proved
to be fatal despite intensive steroid therapy. Larger
observational studies on the effect of rituximab on patients
with prior pulmonary diseases or extensive smoking
history are needed before recommending routine
pre-treatment tests such as pulmonary function tests.
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KEY POINTS
Lung injury such as nonspecific interstitial pneumonia is
a rare but serious side effect of rituximab. Awareness
and education of providers and patients, close
monitoring, and early detection and treatment are key
to preventing fatal incidents of rituximab-induced lung
injury (RTX-ILD). Routine assessment of lung function by
pulmonary function tests should be performed during
treatment with rituximab, especially for patients who
have a previous history of lung disease. Suspicion for
RTX-ILD should prompt discontinuation of the drug and
a therapeutic trial of high-dose steroids, in order to
prevent severe morbidity and mortality.
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